Prognosis
Controversial Alzheimer’s Drug Takes Step Toward FDA Approval
- Aducanumab has been closely watched after study halt, revival
- FDA sets an action date of March 7, though it could act sooner
This article is for subscribers only.
Biogen Inc.’s experimental Alzheimer’s disease treatment aducanumab was granted priority review status by U.S. regulators, a move that could hasten the drug’s arrival on the market.
The company said in a statement Friday that the Food and Drug Administration had granted its application with an action date of March 7, though it said the agency could act earlier under an expedited review.